| Samsung Biologics | Commercial | $74111.8B | Oncology, Autoimmune |
| Chugai Pharmaceutical | Commercial | $14235.4B | Oncology, Autoimmune Diseases |
| Otsuka Holdings | Commercial | $5658.2B | Psychiatry, Neurology |
| Sun Pharmaceutical | Commercial | $4248.3B | Dermatology, Ophthalmology |
| Divis Laboratories | Commercial | $1619.6B | Multi-therapeutic, Generic APIs |
| Torrent Pharmaceuticals | Commercial | $1446.1B | Cardiovascular, Central Nervous System |
| Eisai | Commercial | $1342.9B | Neurology, Oncology |
| Ono Pharmaceutical | Commercial | $1104.0B | Oncology, Immunology |
| Lupin Limited | Commercial | $1059.9B | Respiratory, Cardiovascular |
| Cipla | Commercial | $1017.8B | Respiratory, Oncology |
| SD BioSensor | Commercial | $936.6B | Infectious Disease, Chronic Disease |
| Eli Lilly | Commercial | $811.5B | Diabetes, Oncology |
| Aurobindo Pharma | Commercial | $750.4B | Anti-infectives, Cardiovascular |
| Alkem Laboratories | Commercial | $631.3B | Gastroenterology, Cardiovascular |
| Glenmark Pharmaceuticals | Commercial | $615.4B | Respiratory, Dermatology |
| Abbott India | Commercial | $568.4B | Cardiovascular, Diabetes |
| Johnson & Johnson | Commercial | $567.2B | Oncology, Immunology |
| Santen Pharmaceutical | Commercial | $542.5B | Ophthalmology, Glaucoma |
| Rohto Pharmaceutical | Commercial | $533.6B | Ophthalmology, Dermatology |
| Laurus Labs | Commercial | $533.0B | HIV/AIDS, Oncology |
| KOBAYASHI Pharmaceutical | Commercial | $415.7B | Dermatology, Gastroenterology |
| Ipca Laboratories | Commercial | $388.8B | Anti-malarials, Pain Management (NSAIDs) |
| Jiangsu Hengrui Medicine | Commercial | $366.0B | Oncology, Anesthesia |
| AbbVie | Commercial | $362.6B | Immunology, Oncology |
| AstraZeneca | Commercial | $284.6B | Oncology, Cardiovascular |
| Merck | Commercial | $282.3B | Oncology, Vaccines |
| Gland Pharma | Commercial | $268.2B | Oncology, Critical Care |
| Roche | Commercial | $256.4B | Oncology, Neuroscience |
| Nipro Corporation | Commercial | $242.4B | Renal Disease, Diabetes |
| Towa Pharmaceutical | Commercial | $195.7B | Cardiovascular, Central Nervous System |
| Kissei Pharmaceutical | Commercial | $188.0B | Urology, Nephrology |
| Piramal Pharma | Commercial | $182.5B | Oncology, Critical Care |
| H.U. Group Holdings | Commercial | $177.0B | Oncology, Neurology |
| Natco Pharma | Commercial | $172.3B | Oncology, Hepatology |
| Gilead Sciences | Commercial | $170.3B | HIV/AIDS, Hepatitis |
| PeptiDream | Phase 2 | $154.7B | Oncology, Immunology |
| Neuland Laboratories | Commercial | $154.1B | Oncology, Central Nervous System (CNS) |
| Pfizer | Commercial | $153.4B | Oncology, Internal Medicine |
| BML, Inc. | Commercial | $151.1B | Services - Multi-therapeutic |
| Granules India | Commercial | $146.4B | Pain Management, Anti-infectives |
| Takara Bio | Phase 3 | $138.1B | Oncology, Rare Diseases |
| Alembic Pharmaceuticals | Commercial | $135.4B | Cardiology, Neurology (CNS) |
| Mochida Pharmaceutical | Commercial | $126.7B | Dermatology, Urology |
| Swedish Orphan Biovitrum | Commercial | $124.7B | Rare Diseases, Hematology |
| Vertex Pharmaceuticals | Commercial | $115.4B | Cystic Fibrosis, Sickle Cell Disease |
| GSK plc | Commercial | $104.1B | Respiratory, HIV |
| KYORIN Pharmaceutical | Commercial | $93.8B | Respiratory, Urology |
| Zeria Pharmaceutical | Commercial | $93.1B | Gastroenterology, Dermatology |
| Strides Pharma | Commercial | $83.3B | Infectious Disease, Oncology |
| Nxera Pharma | Phase 2 | $79.5B | Neuroscience, Immuno-oncology |
| Regeneron Pharmaceuticals | Commercial | $77.5B | Ophthalmology, Immunology |
| JCR Pharmaceuticals | Commercial | $72.8B | Rare Diseases, Lysosomal Storage Disorders |
| CSL | Commercial | $67.2B | Hematology, Immunology |
| Takeda Pharmaceutical | Commercial | $56.3B | Oncology, Rare Diseases |
| FDC India | Commercial | $54.2B | Gastroenterology, Cardiology |
| Zoetis | Commercial | $51.0B | Animal Health, Veterinary Medicine |
| Alnylam Pharmaceuticals | Commercial | $41.4B | Rare Diseases, Genetic Disorders |
| Argenx | Commercial | $41.1B | Autoimmune Diseases, Neuromuscular Disorders |
| Shanghai RAAS Blood Products | Commercial | $40.0B | Hematology, Immunology |
| Bayer | Commercial | $37.7B | Oncology, Cardiology |
| Zhifei Biological Products | Commercial | $37.5B | Infectious Disease, Preventive Vaccines |
| SPARC | Phase 3 | $37.3B | Ophthalmology, Neurology |
| Changchun High-Tech Industry | Commercial | $35.8B | Infectious Disease, Oncology |
| Teva Pharmaceutical Industries | Commercial | $33.5B | Central Nervous System, Respiratory |
| Lonza | Commercial | $32.7B | Biologics Manufacturing, Cell & Gene Therapy |
| Agilent Technologies | Commercial | $31.5B | Oncology, Genomics |
| Aarti Drugs | Commercial | $31.4B | Anti-infectives, Anti-inflammatory |
| RPG Life Sciences | Commercial | $31.3B | Critical Care, Women's Health |
| Tiantan Bio | Commercial | $30.7B | Hematology, Immunology |
| Hualan Biological Engineering | Commercial | $27.1B | Infectious Disease, Hematology |
| Royalty Pharma | Commercial | $26.2B | Oncology, Immunology |
| Genscript Biotech | Commercial | $24.3B | Oncology, Hematological Malignancies |
| United Therapeutics | Commercial | $23.0B | Pulmonary Arterial Hypertension, Rare Diseases |
| BioNTech | Commercial | $22.4B | Oncology, Infectious Diseases |
| Bliss GVS Pharma | Commercial | $22.2B | Anti-malarial, Anti-infective |
| LabCorp | Commercial | $21.8B | Oncology, Cardiovascular |
| Hikal | Commercial | $20.8B | Oncology, Central Nervous System (CNS) |
| Exact Sciences | Commercial | $20.0B | Oncology, Cancer Screening |
| Incyte | Commercial | $18.1B | Hematology, Oncology |
| Indoco Remedies | Commercial | $17.6B | Anti-infectives, Cardiovascular |
| Genmab | Commercial | $15.5B | Oncology, Hematology |
| Viatris | Commercial | $15.2B | Cardiovascular, Diabetes |
| Neurocrine Biosciences | Commercial | $12.8B | Neurology, Psychiatry |
| Ipsen | Commercial | $12.3B | Oncology, Rare Diseases |
| Elanco | Commercial | $11.9B | Animal Health, Veterinary Medicine |
| Hester Biosciences | Commercial | $11.8B | Animal Health, Veterinary |
| Dr. Reddy's Laboratories | Commercial | $11.5B | Oncology, Cardiovascular |
| Jazz Pharmaceuticals | Commercial | $11.1B | Rare Diseases, Oncology |
| bioMerieux | Commercial | $10.7B | Infectious Diseases, Microbiology |
| Jamjoom Pharmaceuticals Factory Company | Commercial | $9.7B | Cardiovascular, Anti-infectives |
| Revvity | Commercial | $9.6B | Life Sciences Tools, Diagnostics |
| Abivax | Phase 3 | $9.5B | Inflammatory Bowel Disease, Autoimmune Disorders |
| ImmunityBio | Commercial | $8.7B | Oncology, Bladder Cancer |
| Tempus AI | Commercial | $8.4B | Oncology, Precision Medicine |
| Bio-techne | Commercial | $8.1B | — |
| Charles River Laboratories | Commercial | $7.6B | Oncology, Central Nervous System |
| Arcellx | Phase 1 | $6.7B | Oncology, Hematology |
| Amicus Therapeutics | Commercial | $4.5B | Rare Diseases, Lysosomal Storage Disorders |
| CRISPR Therapeutics | Approved | $4.4B | Hemoglobinopathies, Oncology |
| Amneal Pharmaceuticals | Commercial | $3.7B | Oncology, Neurology (CNS) |
| Indivior PLC | Commercial | $3.7B | Substance Use Disorders, Opioid Use Disorder |
| Synlab | Commercial | $3.3B | General Diagnostics, Chronic Kidney Disease |
| DiaSorin | Commercial | $3.3B | Infectious Diseases, Endocrinology |
| Liquidia Corporation | Approved | $3.2B | Pulmonary Hypertension, Rare Diseases |
| Siegfried Holding | Commercial | $3.2B | — |
| Denali Therapeutics | Phase 3 | $3.2B | Neurodegenerative Diseases, Lysosomal Storage Disorders |
| Virbac SA | Commercial | $2.9B | Companion Animal Health, Livestock Health |
| Vera Therapeutics | Phase 2 | $2.9B | Nephrology, Immunology |
| Tarsus Pharmaceuticals | Commercial | $2.7B | Ophthalmology, Dermatology |
| Twist Bioscience | Commercial | $2.6B | Oncology, Infectious Disease |
| HUTCHMED | Commercial | $2.5B | Oncology, Immunology |
| BB Biotech | Commercial | $2.5B | Oncology, Rare Diseases |
| Dermapharm | Commercial | $2.2B | Dermatology, Cardiovascular |
| Syndax Pharmaceuticals | Phase 3 | $2.1B | Oncology, Hematology |
| Nectar Lifesciences | Commercial | $2.1B | Anti-infectives, Cardiology |
| Celldex Therapeutics | Phase 2 | $2.1B | Oncology, Immunology |
| Bausch Health | Commercial | $1.9B | Gastroenterology, Hepatology |
| Zymeworks | Phase 3 | $1.7B | Oncology |
| Nurix Therapeutics | Phase 1 | $1.5B | Oncology, Immunology |
| Pharma Mar | Commercial | $1.4B | Oncology |
| HBM Healthcare Investments | — | $1.4B | Oncology, Neurology |
| Biohaven | Phase 3 | $1.3B | Neurology, Neuropsychiatry |
| Immatics | Phase 1/2 | $1.3B | Oncology, Immuno-Oncology |
| Monte Rosa Therapeutics | Phase 1/2 | $1.3B | Oncology, Autoimmune Diseases |
| Harrow Health | Commercial | $1.2B | Ophthalmology, Anterior Segment Disease |
| Taysha Gene Therapies | Phase 1/2 | $1.2B | Neurology, Rare Diseases |
| BICO Group | Commercial | $1.2B | Life Science Tools, Drug Discovery |
| MoonLake Immunotherapeutics | Phase 3 | $1.2B | Dermatology, Rheumatology |
| Maravai LifeSciences | Commercial | $1.1B | Genetic Medicine, Infectious Disease |
| Certara | Commercial | $979.5M | Oncology, Rare Diseases |
| Amphastar Pharmaceuticals | Commercial | $896.1M | Endocrinology, Pulmonology |
| Inhibrx Biosciences | Phase 2 | $886.0M | Oncology, Rare Diseases |
| Janux Therapeutics | Phase 1 | $855.3M | Oncology |
| Omeros Corporation | Commercial | $779.9M | Ophthalmology, Hematology |
| MannKind Corp | Commercial | $761.0M | Diabetes, Endocrinology |
| Tilray | Commercial | $723.5M | Chronic Pain, Multiple Sclerosis |
| Pharmanutra | Commercial | $723.1M | Cardiometabolic Health, Musculoskeletal Disorders |
| Nanoform Finland | — | $616.8M | Oncology, Central Nervous System (CNS) |
| MeiraGTx | Phase 3 | $579.5M | Ophthalmology, Neurology |
| Altimmune | Phase 2 | $434.6M | Obesity, Metabolic Diseases |
| Emergent BioSolutions | Commercial | $430.1M | Biodefense, Infectious Disease |
| REGENXBIO | Phase 2 | $418.1M | Ophthalmology, Neurodegenerative Diseases |
| Anavex Life Sciences | Phase 2/3 | $376.2M | Neurodegenerative Diseases, Neurodevelopmental Disorders |
| Evolus | Commercial | $301.9M | Aesthetic Medicine, Neurology |
| Formycon AG | Phase 3 | $301.5M | Ophthalmology, Immunology |
| Amarin Corporation | Commercial | $301.4M | Cardiovascular, Metabolic Disorders |
| Newron Pharmaceuticals | Phase 3 | $291.4M | Neurology, Rare Diseases |
| COLTENE Holding AG | Commercial | $273.7M | Dentistry |
| CARGO Therapeutics | Phase 2 | $210M | Oncology, Hematology |
| OraSure Technologies | Commercial | $203.9M | Infectious Disease, Substance Abuse |
| Quanterix | Commercial | $200.9M | Neurology, Oncology |
| Laboratorio Reig Jofre | Commercial | $199.4M | Dermatology, Hospital & Critical Care |
| Arcturus Therapeutics | Phase 2 | $188.4M | Infectious Diseases, Rare Genetic Disorders |
| Protalix BioTherapeutics | Commercial | $172.1M | Rare Genetic Disorders, Lysosomal Storage Diseases |
| Adagene | Phase 1 | $171.1M | Oncology, Immuno-Oncology |
| Nkarta | Phase 1 | $152.0M | Oncology, Autoimmune Diseases |
| Heron Therapeutics | Commercial | $146.8M | Pain Management, Oncology Supportive Care |
| Global Cord Blood | Commercial | $140.6M | Hematology, Oncology |
| Xlife Sciences | — | $126.9M | Oncology, Immunology |
| Cassava Sciences | Phase 3 | $110M | Alzheimer's Disease, Neurodegenerative Diseases |
| Zomedica Pharmaceuticals | Commercial | $95.3M | Veterinary Medicine, Companion Animal Health |
| Seer Inc | Commercial | $94.8M | Oncology, Neurodegenerative Diseases |
| Precipio | Commercial | $48.8M | Oncology, Hematology |
| Cryo-Cell | Commercial | $25.1M | Hematology, Oncology |
| Dare Bioscience | Phase 3 | $19.4M | Women's Health, Contraception |
| Eterna Therapeutics | Pre-clinical | $7.2M | Regenerative Medicine, Oncology |
| Can Fite Biopharma | Phase 3 | $7.0M | Autoimmune Diseases, Oncology |
| Quince Therapeutics | Phase 1 | $4.5M | Neurodegenerative Diseases, Inflammatory Diseases |
| Genprex | Phase 1/2 | $4.3M | Oncology, Lung Cancer |
| Galmed Pharmaceuticals | Phase 2 | $3.9M | Hepatology, Metabolic Diseases |
| Arcadia Biosciences | Commercial | $3.8M | Nutrition, Metabolic Health |
| PainReform | Phase 3 | $1.8M | Pain Management, Anesthesiology |